SuperworthGlucotrack GCTK
- Market cap
- $284.4K
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $1.7M+290% | $1.7M+188% | $2.1M+235% | $3.6M+472% | $2.1M+22% | $1.7M−3% | $1.9M−13% | $3.1M−12% | $3.2M+53% | $1.6M−4% | $2.1M+14% | $2M−36% |
| SG&A | $531K+7% | $675K | $803K+25% | $902K+63% | $1.2M+124% | $2.2M+219% | $1.6M+103% | $1.6M+83% | $1.1M−4% | $1.9M−14% | $2.1M+27% | $1.4M−16% |
| −$2.2M+139% | −$2.4M+88% | −$3M+130% | −$4.5M+281% | −$3.3M+46% | −$3.9M+60% | −$3.5M+19% | −$4.8M+7% | −$4.3M+33% | −$3.5M−10% | −$4.2M+20% | −$3.4M−29% | |
| Interest expense | n/a | n/a | n/a | n/a | $5K | $39K | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$2.2M+140% | −$2.4M+87% | −$2.9M+128% | −$4.5M+282% | −$5.1M+129% | −$10.1M+319% | −$6.8M+133% | −$4.8M+6% | −$4.2M−18% | −$3.6M−64% | −$4.3M−37% | −$3.8M−20% |
| −$441.00+63% | $495.00 | −$10557.00+2833% | $14760.00+5974% | $16380.00 | n/a | $602.10 | $144.30−99% | $69.60−100% | n/a | $39.75−93% | $11.40−92% | |
| 5.1K+48% | 5.1K+48% | 277−92% | 304.3K+6250% | 311−94% | n/a | 11.3K+3971% | 33K−89% | 60K+19188% | n/a | 109.2K+867% | 333.9K+913% |
EPS, diluted: 12 periods, Q4 FY11 to Q4 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY11 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q2 FY22 and Q3 FY22: not printed by the filing, worked out from its own lines. Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Glucotrack's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GCTKGlucotrack | $284.4K | n/m | n/a | n/m | n/m | n/m | |
| PFSAProfusa | $508.2K | n/m | n/a | n/m | n/m | n/m | |
| VJETFlyte Aviation | $1M | n/m | n/a | 0.5× | +219% | n/m | |
| BBLGBone Biologics | $1.1M | n/m | n/a | n/m | n/m | n/m | |
| IVFINVO Fertility | $1.4M | n/m | n/a | 0.2× | +14% | −70.2% | |
| TNONTenon Medical | $1.5M | n/m | n/a | 0.3× | +80% | n/m | |
| XAIRBeyond Air | $2M | n/m | n/a | 0.3× | +61% | n/m | |
| ADGMAdagio Medical | $2.3M | n/m | n/a | n/a | n/m | n/a | |
| AMIXAutonomix Medical | $2.3M | n/m | n/a | n/m | n/m | n/m | |
| NXGLNexgel | $2.5M | n/m | n/a | n/m | n/m | n/m | |
| BJDXBluejay Diagnostics | $2.6M | n/m | n/a | n/m | n/m | n/m | |
| Peer median | $1.7M | n/a | n/a | 0.3× | +70% | −70.2% |
More on Glucotrack
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .